 WINNIPEG, MB, Aug. 27, 2021 PRNewswire - Medicure Inc. Medicure or the Company TSXV: MPH OTC: MCUJF, a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2021. Quarter Ended June 30, 2021 Highlights: Recorded total net revenue from the sale of products of 5.09 million during the second quarter ended June 30, 2021 compared to 2.68 million for the second quarter ended June 30, 2020; Recorded total net revenue from the sale of AGGRASTAT of 2.8 million during the second quarter ended June 30, 2021 compared to 2.6 million for the second quarter ended June 30, 2020; Net loss for the second quarter ended June 30, 2021 was 639,000 compared to net income of 19,000 for the second quarter ended June 30, 2020; Adjusted earnings before interest, taxes, depreciation, and amortization EBITDA1 for the second quarter ended June 30, 2021 was 158,000 compared to adjusted EBITDA of 263,000 for the second quarter ended June 30, 2020 Financial Results Net revenues for the three months ended June 30, 2021 were 5.09 million compared to 2.68 million for the three months ended June 30, 2020. 